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INTRODUCTION
Induction of labor is defined as the initiation
process of uterine contractions with the help of
medical pharmacology or medical action before the
onset of spontaneous parturition.1 Approximately
20% of births in the United States and Britain
begins with induction of labor, whereas the
incidence of labor induction in Africa and Asia
are 4.4% and 12.1% of all deliveries, respectively.
This proportion will continue to increase
significantly almost several years.2-4
Abstract
Objective: To compare the efficacy and safety of hourly titrated oral
misoprostol in solution (OMS) with vaginal misoprostol (PV) for
labor induction.
Methods: Randomized Controlled Trial (RCT), double blind-add on
the study was conducted from January-November 2016 in delivery
ward of Moh. Hoesin general hospital. Women 30 weeks of gesta-
tion with an unfavorable cervix (Bishop score 6) and an indication
for labor induction were randomly assigned to receive titrated oral
or vaginal misoprostol. The OMS group received a basal unit of
20 ml misoprostol solution (1 g/ml) every 1 hour for four doses
and then were titrated against individual uterine response. In the
absence of regular uterine contractions, the dose was increased to
40 ml hourly for four doses and then 60 ml for four doses. The
vaginal group received 25 g every 4 hours until attaining a more
favorable cervix for three doses. All the subjects received amylum
placebo. In labor within 12 hours was the primary outcome.
Results: A total of 30 women were enrolled in this study. One sub-
ject in the OMS group was dropped out due to eclamptic seizure. The
average interval from induction until in labour in OMS group was
5.753.14 hour and 6.604.46 hour in PV group (p = 0.56). In labour
stage was achieved within 12 hours in 14 women (100%) in OMS
group and 14 women (93.3%) in PV group (p = 1.00). Vaginal
delivery was achieved within 24 hours in 13 women (92.9%) in
OMS group and 15 women (100%) in PV group. The incidence of
uterine hyperstimulation/ tachysystolic was 7.1% in OMS group
compared with 13.3% in PV group. Fetal distress was found only 1
case (7.1%) in OMS group. There was no difference in the maternal
and neonatal outcome of labor in both the groups.
Conclusion: Oral titrated in solution, and vaginal route of
administration of misoprostol for induction of labour are
equally effective and safe.
[Indones J Obstet Gynecol 2018; 6-2: 89-97]
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Abstrak
Tujuan: Membandingkan efektivitas dan keamanan pemberian laru-
tan misoprostol titrasi peroral/ titrated oral misoprostol in solution(OMS) dan misoprostol pervaginam (PV) untuk induksi persalinan.
Metode: Randomized Controlled Trial (RCT), double blind-add on di-lakukan Januari-November 2016 di kamar bersalin RSUP Dr. Moh.
Hoesin Palembang. Terdapat 30 subjek wanita hamil dengan usia
gestasi 30 minggu dan skor Bishop 6 yang memenuhi indikasiinduksi persalinan; selanjutnya dirandomisasi menjadi 2 kelompok,
yaitu OMS dan PV. Subjek pada kelompok OMS menerima misoprostol
peroral 20 ml/jam (1 g/ml) sebanyak 4 dosis. Bila kontraksi uterus
yang regular belum timbul, dosis dinaikkan menjadi 40 ml/jam se-
banyak 4 dosis. Bila kontraksi regular belum timbul, dosis dinaikkanmenjadi 60 ml/jam sebanyak 4 dosis. Subjek pada kelompok PV
menerima misoprostol pervaginam 25 g/4 jam sebanyak 3 dosis.
Setiap subjek juga menerima plasebo amilum. Parameter keberhasil-
an penelitian adalah keberhasilan mencapai inpartu 12 jam.
Hasil: Dari 30 subjek, 1 orang pada kelompok OMS drop out dari
penelitian karena eklampsia berulang. Rerata interval induksi-inpartu
pada kelompok OMS 5,753,14 jam, sedangkan kelompok PV
6,604,46 jam (p = 0,56). Sebanyak 14 subjek (100%) pada kelompok
OMS dan 14 subjek (93,3%) pada kelompok PV mencapai inpartu 12
jam (p = 1,00). Partus pervaginam 24 jam dicapai 13 subjek (92,9%)pada kelompok OMS dan 15 subjek (100%) pada kelompok PV
(p = 0,48). Kasus hiperstimulasi/takisistolik uterus ditemukan pada1 subjek (7,1%) pada kelompok OMS dan 2 subjek (13,3%) pada
kelompok PV. Komplikasi gawat janin ditemukan pada 1 subjek
(7,1%) pada kelompok OMS. Tidak ditemukan perbedaan bermaknaluaran maternal dan neonatus pada kedua kelompok.
Kesimpulan: Larutan misoprostol titrasi peroral memiliki efektivitasdan keamanan yang sama dengan misoprostol pervaginam untuk
induksi persalinan.
[Maj Obstet Ginekol Indones 2018; 6-2: 89-97]
Kata  kunci: larutan misoprostol titrasi oral perjam, misoprostol
peroral, misoprostol pervaginam, uji klinik acak berpembanding
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Misoprostol is a synthetic analog of prosta-
glandin E1 that is inexpensive, stable at room
temperature, easily stored, and simple in usage for
cervical ripening and induction of labor. However,
misoprostol can cause fetal distress due to uterine
hyperstimulation or tachysystole uterus. To avoid
hyperstimulation or tachysystole uterus and to
shorten the induction interval up to labor,
misoprostol should be given in small, effective
doses, in a high frequency, and titrated according
to uterine response. Oral titrated misoprostol
solution administration or oral misoprostol in
solution (OMS) fulfilled all aforementioned criteria.
In addition, divided doses of misoprostol proved to
be disadvatageous due to a difficult and imprecise
tablet cutting, rendering the dosage to be
inappropriate. OMS administration does not only
allow the proper dosage, but misoprostol can
remain active in the solution for 24 hours.5
Cheng, et al. compared the efficacy and safety of
OMS and vaginal misoprostol for induction of labor
in pregnant women 34-42 weeks with a Bishop
score  6. OMS were given with an initial dose of
20 mcg/ hour and repeated for every hour until
adequate uterine contractions were achieved.
When the contractions are not adequate after four
times of administration, the dose was increased to
40 mcg/hour and repeated every hour until ade-
quate contraction, with a maximum of 4 doses.
When the contractions were not adequate after 8
hours from the start of induction, then the dose
was increased to 60 mcg/hour until adequate
uterine contractions were achieved with a
maximum of 4 doses. If the patient has become in
labor, then misoprostol is stopped. When the
contractions become inadequate before the active
phase of labor, then the introduction of OMS can
be repeated, starting at a dose of 10 mcg/hour and
can be raised to 20 mcg/hour, or up to 40 mg/hour
based on the response of the uterus to achieve
adequate uterine contractions. Delivery within 24
hours was achieved in 94.1% of the 101 women
who were randomly assigned oral titrated miso-
prostol solution, compared with 53.8% of the 106
women given misoprostol vaginally (p = 0.01). No
women of the OMS group developed uterine hyper-
stimulation, while 11.3% in the vaginal misopros-
tol group did. Although more women experienced
nausea in the OMS group (10.9%), the newborn
Apgar score in this group is better (>7 at 1 minute
first) than the vaginal group. Cheng, et al. con-
cluded that low doses of titrated misoprostol are
associated with a low incidence of uterine hyper-
stimulation and cesarean section compared with
vaginal misoprostol in women with the immature
cervix.6 In another literature, Cheng concluded
OMS is more effective and superior to vaginal
misoprostol. By administering OMS, the rate of
vaginal delivery becomes higher which decreases
the rate of cesarean section.7
This study aims to compare the efficacy and
safety of oral titrated misoprostol solution (OMS)
with vaginal misoprostol (per vaginal misoprostol/
PV) in women undergoing labor induction.
METHOD
This study was a Randomized Controlled Trial
(RCT), double-blind, add-on study and had
received ethics approval from the Ethics
Committee of Dr. Moh. Hoesin Hospital Palem-
bang. The study involved 30 pregnant women who
meet the inclusion criteria during the period from
January to November 2016. Inclusion criteria for
the study were pregnant women 30 weeks,
fulfilling an indication of induction of labor, a
single live fetus pregnancy, Bishop score 6,
cephalic presentation, normal fetal heart rate
patterns, and willing to participate in the study
by signing a letter of approval (informed
consent). Exclusion criteria included pregnant
women with contraindications of vaginal delivery,
previous cesarean section, a history of surgery on
the uterus, intrauterine fetal death, parity > 5,
the presence of adequate uterine contractions,
and abnormal fetal heart rate patterns or fetal
distress. Drop out criteria were a h istory  of
allergy to misoprostol; patients experience
side effects that heavy drug misoprostol (adverse
effects), such as anaphylactic shock, imminent
uterine rupture and uterine rupture; additional
diagnoses that can stop the study procedures
(eg, eclampsia, impending eclampsia, HELLP
syndrome, and so on, which leads to the abdominal
termination); or the patient does not comply with
the study protocol. Withdrawal criteria were
patients who decide to stop participating in
the study on their own without any coercion.
The samples were divided into two groups
derived from simple randomization using
randomization tables. At the titrated oral
misoprostol group (OMS), a solution of misoprostol
was given orally according to the study protocols,
and one placebo tablet which will be divided into
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c parts and administered vaginally in the
posterior fornix according to the study protocols.
In the group of vaginal misoprostol (PV), one
placebo tablet was dissolved in 200 ml of water
in a glass and administered according to the
appropriate protocol, and one tablet of misoprostol
200 mcg which will be divided into c parts (25g)
and administered in the posterior vaginal fornix.
Regimens in the two groups of these samples
were administered without the knowledge of re-
searchers (blinded). Material samples have been
coded "OMS" or "PV" and put in a sealed envelopes
which have been given a random number based
on the randomization tables by individuals not
directly involved in the study. Before the envelope
is closed and sealed, the envelope code is recorded
on a special sheet and stored separately in a sealed
envelope to be opened at the time of data analysis
is complete. Researchers and patients did not know
the contents of the drug given to the patient.
Misoprostol effectiveness was assessed by
achieving successful in labour 12 hours after
induction began. OMS and PV safety was assessed
by observing drug side effects in both maternal and
neonatal outcomes. Failed induction was defined as
failure to achieve inabour after 12 hours from the
start of administration of misoprostol. Uterine
hyperstimulation was defined as the presence of
excessive uterine contraction with fetal heart rate
abnormalities. Changes in fetal heart rate were
defined as persistent decelerations, tachycardia, or
a decrease in short-term variability. Tachysy stole
uterus was defined as the presence of uterine
contractions > 5 times within 10 minutes, which
lasted an average of > 30 minutes without changes
in fetal heart rate.
In OMS protocol, one tablet misoprostol (200
g) was dissolved in 200 ml water in a medical
measurement bottle and mixed evenly. Misoprostol
solution should be used within 24 hours after
dissolved. OMS was given with an initial dose
of 20 ml/hour and repeated every hour until
adequate uterine contractions were achieved.
When the contractions did not occur or not
adequate after four times of administration, the
dose was increased to 40 ml/hour and repeated
every hour until adequate contractions were
achieved, with a maximum of 4 doses. When the
contractions were not adequate after 8 hours
from the start of induction, then the dose was
increased to 60 ml/hour until adequate uterine
contractions were achieved with a maximum of 4
doses. Adequate uterine contractions were defined
as the presence of three or more uterine contrac-
tions in a 10-minute period with a duration  30
seconds.7
When adequate uterine contractions have been
achieved in 1 hour, misoprostol was subsequently
terminated. If the patient has reached in labour,
then misoprostol is stopped. When the contrac-
tions become inadequate after parturients entered
labour, acceleration with oxytocin is possible to
administer at least 2 hours after the last adminis-
tration of misoprostol. Acceleration of labor is
achieved with oxytocin 5 IU mixed in 500 ccs
of Ringer Lactate. During the first 15 minutes,
oxytocin is given ten drops/min, then increased
five drops every 15 minutes until the adequate
contraction is reached or a maximum of 40
drops/minute. If the Bishop score has reached  9,
amniotomy may be done according to the doctor’s
discretion. If there is a failed induction, parturients
are managed by standard procedure at the
Obstetrics and Gynecology Department of Dr.
Moh. Hoesin Hospital Palembang.
In PV protocol, the initial dose of 25 g vaginal
misoprostol is administered in the posterior
vaginal fornix. This dose can be repeated every 4
hours to achieve adequate uterine contractions.
Adequate uterine contractions were defined as the
presence of three or more uterine contractions in
a 10-minute period with a duration  30 seconds.
When adequate uterine contractions have been
achieved in 1 hour, then misoprostol is sub-
sequently terminated. If the patient has reached
in labour, then misoprostol is stopped. When the
contractions become inadequate after parturients
entered labour, acceleration with oxytocin is
possible to a d m i n i s t e r  a t  l e a s t  2  h o u r s
a f t e r  t h e  l a s t  administration of misoprostol.
If the Bishop score has reached  9, amniotomy
may be done according to the doctor’s discretion.
If there is a failed induction, parturients are
managed by standard procedure at the Obstetrics
and Gynecology Department of Dr. Moh. Hoesin
Hospital, Palembang, Indonesia.
Fetal heart rate and uterine contractions are
closely monitored using cardiotocography from the
beginning of induction until delivery. Data were
analyzed using SPSS 18. Dichotomous variables
were compared between the two groups using
Chi-square test, whereas continuous variables
were compared using the Student t-test. A p
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value less than 0.05 was considered as statistically
significant.
RESULTS
A total of 30 subjects were divided into two groups;
the OMS (15 pregnant women who received
induction treatment with oral titrated misoprostol
solution and vaginal placebo) and PV groups (15
pregnant women who received induction treat-
ment with vaginal misoprostol and placebo oral
titration solution). After follow-up, there is one
subject on which the OMS group who dropped out
because of recurrent eclamptic seizures.
Table 1 shows the demographic characteristics
of the subjects and indications of induction of
labor. No significant difference was found between
the demographic characteristics of subjects in both
groups. Highest indication of induction in both
groups was preeclampsia. However, the numbers
of subjects with pre-eclampsia were higher in PV
group compared to the OMS group.
The average interval from induction (starting
after the first dose of misoprostol) until in labour
in the OMS group was 5.75  3.14 approximately
60 minutes faster than the 6.60  4.46 hours found
in the PV group. The average induction to delivery
interval occurs more quickly in the OMS group
(10.11  6.17 hours) than the PV group (11.33 
6.24 hours). However, statistical analysis revealed
that the difference was not significant (p = 0.599).
The mean dose of misoprostol in the OMS group
was 4 times higher than the PV, but it is reasonable
from the standpoint of drug pharmacodynamics.
All subjects (100%) in the OMS group reached
in labour 12 hours, while the PV group had one
subject (6.7%) with failed induction. The diagnosis
of the subject who had a failed induction by vaginal
misoprostol is a post-termpregnancy (gestational
age 41-42 weeks). This particular subject was in-
duced with IV oxytocin and managed to achieve
spontaneous labor. The use of oxytocin in the OMS
group is less than the PV group. All subjects in the
PV group achieved spontaneous delivery, whereas
in the OMS group there is 1 subject (7.1%) who
needed abdominal termination due to prolonged
latent phase and 1 subject (7.1%) terminated
by forceps extraction due to maternal ventricular
septal defect.
Table 1. Characteristics of the Subjects
Variables
OMS PV
p value
n % n %
Mean maternal age (years) 28.64  6.54 30.67  6.14 0.397*
Mean gestational age (weeks) 37.79  2.36 38.67  27.9 0.369*
Mean Bishop score 3.57  1.02 3.40  0.99 0.648*
Bishop score
 4 7 50 8 53.3 1.000
5-6 7 50 7 46.7 **
Body mass index
Nonobese (18-24.9) 3 21.4 4 26.7 1.000
Obese (25) 11 78.6 11 73.3 ***
Parity
Nullipara 9 64.3 8 53.3 0.825
Multipara 5 35.7 7 46.7 **
Induction indication
Preeclampsia 5 35.7 6 40
Postterm/postdate 0 0 4 26.7
Oligohidramnion 4 28.5 2 13.3 0.145
PROM 2 14.2 2 13.3 ****
Others 3 21.4 1 6.7
* Unpaired T-test; p = 0.05
** Chi-square test*** Fischer exact test****Pearson correlation test
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Table 2. Labour Outcome Characteristics
Variables
OMS PV
p value
n % n %
Induction-inlabour interval (hours) 5.75  6.54 6.60  4.46 0.560* *
Induction-active phase interval (hours) 7.25  2.36 8.07  5.53 0.686*
Induction-delivery interval (hours) 10.11  1.02 11.33  6.24 0.599*
Total misoprostol dose (g) 218.57  147.27 50.00  23.15
Vaginal delivery  12 hours
Yes 9 64.3 10 66.7 1.000
No 5 35.7 5 33.3 **
Vaginal delivery  24 hours
Yes 13 92.9 15 100 0.483
No 1 7.1 0 0 ***
Oxytocin acceleration
Yes 5 35.7 6 40 1.000
No 9 64.3 9 60 **
Failed induction
Yes 0 0 1 6.7 1.000
No 14 100 14 93.3 ***
Delivery type
Spontaneous 12 85.7 14 93.3
Operative 1 7.1 0 0 0.316
vaginal ****
Abdominal 1 7.1 0 0
* Unpaired T-test; p = 0.05
** Chi-square test*** Fischer exact test****Pearson correlation test
Table 3. Maternal and Neonatal Outcome Characteristics
Variables
OMS PV
p value
n % n %
Hyperstimulation
Yes 1 7.1 1 6.7 1.000*
No 1 92.9 14 93.3
3
Tachysystolic uterus
Yes 0 0 1 6.7 1.000*
No 1 100 14 93.3
4
Uterine rupture
Yes 0 0 0 0 1.000*
No 1 100 15 10
4 0
Postpartum hemorrhage
Yes 0 0 0 0 1.000*
No 1 100 15 10
4 0
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Table 3 shows maternal and neonatal out-
comes on the use of drugs in both groups. There
were no significant differences in maternal out-
come variables between the two groups. In the
OMS group of, there is one subject (7.1%) who
developed uterine hyperstimulation following
administration of oral misoprostol 480 ml within
11 hours. The induction on this particular subject
is antepartum eclampsia. While in the PV group,
there is one subject (6.7%) who developed uterine
hyperstimulation following administration of
vaginal misoprostol 75 mg in 12 hours and 1
subject (6.7%) with a tachysystole uterus. The
induction indications of these subjects were fetal
Variables
OMS PV
p value
n % n %
Shivering
Yes 4 28.6 6 40 0.700*
No 1 71.4 9 60
0
Fever
Yes 0 0 0 0 1.000*
No 1 100 15 10
4 0
Nausea
Yes 1 7.1 0 0 0.483*
No 1 92.9 15 10
3 0
Vomiting
Yes 1 7.1 0 0 0.483*
No 1 92.9 15 10
3 0
Diarrhea
Yes 0 0 0 0 1.000*
No 1 100 15 10
4 0
Meconium staining
Yes 6 42.9 5 33.3 0.885*
No 8 57.1 10 66.7
Fetal distress
Yes 1 7.1 0 0 0.483*
No 13 92.9 15 100
APGAR score at 1 min
<8 3 21.4 3 20 1.000*
8 11 78.6 12 80
APGAR score at 5 min
<8 2 14.3 2 13.3 1.000*
8 12 85.7 13 86.7
NICU admission
Yes 1 7.1 2 13.3 1.000*
No 13 92.9 13 86.7
Perinatal death
Yes 0 0 1 6.7 1.000*
No 14 100 14 93.3
*Fischer exact test
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congenital abnormality and preeclampsia respec-
tively. Subjects from the PV group complained
more chills (40%) than the OMS group (28.6%).
Misoprostol was immediately discontinued in case
of uterine hyperstimulation and tachysystole
uterus. Furthermore, patients were given 10 mg of
nifedipine and fetal heartbeats were monitored
closely. Neonatal outcomes are relatively similar in
both groups. Fetal distress was found in 1 subject
(7.1%) with a gestational age of 31 weeks and
an indication of antepartum eclampsia, which
received OMS. Fetal distress occurs during the
active phase due to hypoxia.
All subjects (100%) in the OMS group reached
inlabour  12 hours, while 14 subjects (93.3%) of
the PV group reached inlabour  12 hours. There
were no efficacy differences between oral titrated
solution misoprostol with vaginal misoprostol in
achieving inlabour  12 hours (p = 1.000).
Furthermore, this study resulted with a cut-off
point of induction-inlabour interval at 4.75 hours.
Based on the cut-off point, there were no
differences between the oral misoprostol and
vaginal misoprostol groups (p = 1.000, p > 0.05).
DISCUSSION
The study found no significant differences of mean
age, mean gestational age, mean Bishop score,
parity, and induction indications of labor between
the two groups. The most common indication of
labor induction is hypertension in pregnancy. A
study by Rouzi, Madhavi, and Cheng also had
similar results, but the most common indication in
their study was post-term pregnancy. The third
study was an RCT designs, but single blinded. The
inclusion criteria between these studies were
similar; Rouzi and Cheng used an inclusion criteria
of 34-42 weeks’ gestation; while Madhavi
examined only 38-41 weeks gestation term.
Furthermore, Madhavi used 60 samples, Rouzi
used 160 samples, Rouzi and Cheng used a larger
sample size of 207 samples.5-8
The study also found no significant difference
between the mean induction-inlabour and
induction-labor intervals between groups. The
mean induction-inlabour interval in the OMS
group were 5.75  3.14 hours and 6.60  4.46
hours in the PV group. Rouzi, et al. also failed to
observe a significant difference in the induction-
in labour interval. In his study, the mean
induction-labor interval in the OMS group was
17.6  8.5 hours and 20.2  18 hours in the PV
group.5 Madhavi also found no significant
differences in induction to delivery interval
between OMS and and PV groups. The mean
induction-labor ineterval in the OMS group was
13.83 hours and 13.82 hours in PV group
(p = 0.994).8
Conversely, Cheng, et al. obtained significant
difference of intervals until labor between OMS and
PV groups. The mean induction - vaginal delivery
interval was 8.2 hours in the OMS group and 17.6
hours in the PV group (p <0.01). The latent phase
was 6.5 hours in the OMS group and 13.4 hours in
the PV group; while the active phase was 1.6 hours
in the OMS group and 3.4 hours in the PV group
(p <0.01).6,7 In contrast to these results, Ashalatha
observed a significant difference in mean induction
- labor interval in both groups. According to
Ashalatha, vaginal misoprostol has a shorter
induction - labor interval shorter compared with
oral titrated misoprostol, with 17.8 hours in the PV
group and 27.9 hours in the OMS group, with a
mean difference of 10.1 hours.9 The study by
Cheng had inclusion criterias and study protocols
that were almost similar to this study, but the
large number of samples resulted in significant
differences regarding the effectiveness between
the two groups. Ashalatha, et al. used misoprostol
dose titration per hour, but with a larger sample
size of 245 samples. Madhavi used a protocol of
OMS dose per 2 hours with a small sample size (n
= 60), and the results were similar to the results
of this study. Differences in failed induction
criterias may also lead to a diversity of results.
Factors such as infection, sweeping of the
membrane, and amniotomy were also not
controlled in this study.
The mean dose of misoprostol in the PV group
is lower than the OMS group. This is due to the
pharmacokinetics of misoprostol, which is different
for each route of administration. Onset of action of
oral misoprostol started at 8 minutes, a maximum
half-life at 30 minutes, and a duration of 2 hours.
When administered vaginally, the onset of
action of misoprostol begins after 20 minutes of
administration, the half-life of up to 70 minutes,
and a duration of 4 hours. Therefore, vaginal
misoprostol remains effective for a longer time
and the total dose required for induction of labor
is lower.10
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This study did not observe any oxytocin
acceleration incidence difference between the two
groups. Acceleration oxytocin were indicated in 5
subjects (35.7%) in the OMS group and 6 (40%) in
the PV group. Madhavi also obtain similar results.
In the study by Madhavi, 26.7% of the subjects in
the OMS group and 20% of the subjects in the PV
group required oxytocin acceleration (p = 0.542).8
Conversely, Cheng, et al. only found 10.9% of the
subjects in the OMS group of CSOs who required
oxytocin. This percentage is much less than 53.8%
of the subjects in the PV group that required
oxytocin acceleration (p = 0.01).6 Another study by
Ashalatha found that fewer oxytocin acceleration
were indicated in the PV group (39%) compared
to OMS (58.2%) group.10
In this study, all subjects in the PV intervention
group is treated by spontaneous labor. Whereas in
the OMS group, spontaneous labor occured in 12
subjects (85.7%), extraction forceps and cesarean
section respectively in 1 subject (7.1%). Indication
for forceps extraction is maternal cardio decom-
pensation with a ventricular septal defect, so it is
actually not related to the labor disruption at the
second stage. Indication of cesarean section on the
subject of this study is prolonged latent phase.
There were no significant differences regarding the
type of delivery between the OMS and PV groups
according to Madhavi (p = 0.43).8 Cheng, et al. also
concluded that the incidence of uterine hyper-
stimulation and cesarean sections are lower when
misoprostol is administered orally in titrated
solution.6
The study found no differences in maternal out-
comes between the two groups. Uterine hyper-
stimulation was found in one subjects with a
diagnosis of P 3 G 4 A 0 31 weeks pregnant with
antepartum eclampsia, single live fetus and head
presentation in the OMS group, which then reached
the active phase. Uterine hyperstimulation was
managed with fetal resuscitation, administration of
nifedipine, and planned abdominal termination.
But in the preparatory period of operation, the
subject reached the second stage of labour. The
fetus was born spontaneously with only 1400
grams birth weight and an Apgar score of 3/5/7.
After undergoing intensive care in the NICU for 21
days, the baby’s condition is healthy and stable.
Nausea, vomiting, and shivering were quite
observable symptoms which disappears after two
hours of observation. Uterine hyperstimulation in
the PV group was found in one subject a diagnosis
of G 1 P 0 A 0, pregnant for 31 weeks, single live
fetus with a head presentation + polyhydramnios
+ congenital abnormalities (there are findings of
deformities of the heart, spinal deformity, single
umbilical artery, echogenic bowel, hydrocele,
ascites and claw hand) with a biophysical profile
score of 8. When uterine hyperstimulation
occured, the subject had reached 6 cm cervical
dilatation and the fetus experienced tachycardia.
Approximately 10 minutes after hyperstimulation
of the uterus, the fetus is born spontaneously with
1 minute Apgar score of 1, and 5 minutes later the
fetus died. The cause of perinatal death in this case
is likely due to major congenital abnormalities.
Madhavi only found 1 subject (3.3%) in the PV
group who experienced uterine hyperstimulation
and was treated by administration of terbutaline
250 mcg via subcutaneous injection. Misoprostol
side effects such as nausea, vomiting, diarrhea, and
fever were not found in the study by Madhavi.8
Cheng et al. reported that oral and vaginal
misoprostol are equally safe for the mother. Cheng
reported misoprostol mild side effects such as
nausea (10.9%), vomiting (8.9%), and diarrhea
(5%) in the OMS group.6
In the OMS group, there were 6 cases of thick
meconium staining. While in PV group, there were
5 cases of thick meconium staining. This incident
may be triggered by the high-risk pregnancies,
such as post-term pregnancy accompanied
by oligohydramnios, premature rupture of
membranes more than one day, and preeclampsia/
eclampsia. Madhavi reported 2 cases (6.7%) of
thick meconium staining in the OMS group and 2
cases (6.7%) in the PV group. Both cases of thick
meconium staining in the OMS group underwent
cesarean sections, where the first case were caused
by a non-reassuring CTG and the other cases by
arrest of labor. In the PV group, two cases with
thick meconium staining underwent cesarean
section due to non-reassuring CTG. The four
neonates in the study by Madhavi did not require
NICU care and did not experienced respiratory
failure syndrome.8 The same was reported by
Ashalatha, where the incidence of thick meconium
staining is more common in oral compared to
vaginal misoprostol.9 In this study, we observed
one neonate from the OMS group who needed
NICU treatement, where the gestation age was 31
weeks, the fetus is born prematurely with low
birth weight (1400 grams), and the newborn
developed respiratory failure syndrome. While in
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PV group, there are two neonates who required
NICU care. One case was treated in the NICU
because of a congenital heart defect, and the
other due to respiratory failure syndrome.
There were no differences in the efficacy of oral
titrated misoprostol solution and vaginal miso-
prostol in achieving inlabour  12 hours. Similar
results were also obtained from the study by
Madhavi. Madhavi concluded that administration
of oral and vaginal misoprostol has the same effec-
tiveness for labor induction.8 Zvandasara et al.
conducted a similar research at the University
Hospital of Zimbabwe involving 69 pregnant
women in the O|MS group and 65 pregnant women
in the PV group. The study concluded that the
effectiveness and safety of OMS is similar with PV
for induction of labor, even in poor countries
where intrapartum supervision is often inade-
quate. Subjects induced by OMS have a faster
induction- initiation of uterine contraction interval
(OR = 0.94; 95% CI = 0.42-2.12), but with a longer
duration of labor (OR, 0.36; 95% CI 0,16- 0.79).
Acceleration of oxytocin were more common in the
OMS group.11 In contrast, Cheng, et al. reported
that oral titrated misoprostol may furtherly
shorten the interval from induction to vaginal
delivery compared to vaginal administration. In
addition, the percentage of vaginal delivery  12
hours were more common in the OMS group
compared to PV (p = 0.01, RR = 8.44 [4.52 to
15.76]). The percentage of vaginal delivery  24
hours are also more common in the OMS compared
to PV; with a p-value = 0.01 and RR 13.61 (5.49 to
33.78). Failed induction is more common in PV
group.6
This study is a double blind RCT-add on, thus
ensuring the strength of the end results.
Randomization in this study aims to create similar
characteristics between groups. This study also
conducted a double-blinding, where researchers
and survey respondents did not know the status of
the respondent whether they were included in the
intervention or non-intervention group. The
strength of this design can minimize confounding
factors that may lead to bias in the results. Placebo
used in this study is made of starch which is inert,
does not have a pharmacological effect, and mimics
the appearance, taste, and smell of misoprostol
(Cytotex). The weakness of this study is the small
sample size of just 30 people, thus resulting in the
possibility of low precision. In addition, several
confounding factors that can accelerate the onset
of labor such as infection, sweeping of the
membrane, and amniotomy were also not
controlled in this study.
CONCLUSION
Oral titrated misoprostol in solution and vaginal
misoprostol are equally effective for achieveing in
labour within 12 hours. There was no difference in
maternal and neonatal outcome of labour in both
the groups.
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